Gene test could match eye patients to best drug, save vision
NCT ID NCT06952452
Summary
This study aims to see if a person's genes can predict which of two common eye injections works better for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It will follow 630 patients for 3 years, comparing the standard drug ranibizumab with the more cost-effective bevacizumab. The goal is to help doctors personalize treatment to better control the disease and preserve patients' eyesight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitario de Canarias
RECRUITINGSan Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Contact
Contact Email: •••••@•••••
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Spain
Contact
Contact Email: •••••@•••••
-
Hospital la Esperanza
RECRUITINGBarcelona, Spain
Contact
Contact Email: •••••@•••••
-
Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC La Paz)
RECRUITINGMadrid, 28046, Spain
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.